Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREACH trial of brentuximab vedotin plus AVD versus ABVD in untreated early-stage unfavorable Hodgkin lymphoma
NL-OMON55642Phase 2Recruiting
- Sponsor
- LYSARC
- Start
- Apr 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by LYSARC. Primary endpoint: PET negativity after two cycles. Started Apr 2016; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON55642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55642.